Pharma AI Infrastructure: 2026 Deals and Investments
Examine 2026 AI infrastructure investments in pharmaceutical R&D. This report details the Lilly-NVIDIA lab, Earendil funding, and GPU compute deployments.
Back to Articles
Articles tagged with “pharmaceutical-r-d”
ELN vs LIMS vs SDMS: Guide to Pharma Lab Informatics
Compare ELN, LIMS, and SDMS for pharmaceutical labs. This 2026 guide explains architectural differences, features, compliance, and specific R&D use cases.
Build vs Buy AI in Pharma: R&D and Commercial Guide
Analyze the build vs buy AI decision in pharma. Compare costs, risks, and time-to-value for R&D and commercial teams to guide strategic investment.
Measuring AI ROI in Drug Discovery: Key Metrics & Outcomes
Learn how to measure AI ROI in drug discovery beyond cost and time savings. This guide explains key metrics for scientific outcomes, pipeline productivity, and
Open Source Pharma: Tools & Trends in Drug Development
Learn how open source software like R and Python is changing pharma R&D. From Novo Nordisk's first R-based FDA submission to AlphaFold 3's open-sourcing, we analyze the accelerating shift from proprietary systems to collaborative drug discovery models.
GPTeal: Merck’s Generative AI Strategy for Pharma R&D
An in-depth analysis of Merck's GPTeal platform and expanding AI strategy. Covers the KERMT drug discovery model, Mayo Clinic partnership, CSR automation results, and enterprise-scale LLM deployment across pharma R&D.